Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

VEGF inhibitors described by Zeneca

Oct. 24, 1997

Dusa reports positive phase III results for Levulan PDT

Oct. 24, 1997

Preclinical results with L-methioninase presented at cancer meeting

Oct. 23, 1997

Antiproliferative quinazoline derivatives disclosed at Zeneca

Oct. 23, 1997

NeoPharm moves LED to phase I for prostate cancer

Oct. 22, 1997

Pharmacyclics enters into licensing agreement with Nycomed for Lu-Tex

Oct. 21, 1997

Potential new anticancer vaccines described

Oct. 21, 1997

Yale-Vion developing bacteria-based cancer treatment

Oct. 21, 1997

Peptech reaches phase I goals for antagonist G; exercises license option

Oct. 20, 1997

ImClone and CombiChem enter alliance for drug discovery in oncology

Oct. 20, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...